Notice2024-05776
Notice of Award of a Sole Source Cooperative Agreement To Fund Rwanda Biomedical Center (RBC)
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
March 19, 2024
Issuing agencies
Health and Human Services DepartmentCenters for Disease Control and Prevention
Abstract
The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces the award of approximately $17,500,000, for Year 1 funding to RBC. The award will support a sustainable, affordable, integrated, and country- led HIV/AIDS clinical and public health program in Rwanda. Funding amounts for years 2-5 will be set at continuation.
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 54 (Tuesday, March 19, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 54 (Tuesday, March 19, 2024)]
[Notices]
[Pages 19592-19593]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-05776]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Notice of Award of a Sole Source Cooperative Agreement To Fund
Rwanda Biomedical Center (RBC)
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), located
within the Department of Health and Human Services (HHS), announces the
award of approximately $17,500,000, for Year 1 funding to RBC. The
award will support a sustainable, affordable, integrated, and country-
led HIV/AIDS clinical and public health program in Rwanda. Funding
amounts for years 2-5 will be set at continuation.
DATES: The period for this award will be September 30, 2024, through
September 29, 2029.
FOR FURTHER INFORMATION CONTACT: Antyme Kayisabe, Center for Global
Health, Centers for Disease Control and Prevention, 30 KG 7 Avenue
(Kacyiru), P.O. Box 28 Kigali, Rwanda, telephone: 788382114, e-Mail:
<a href="/cdn-cgi/l/email-protection#3159404008715255521f565e47"><span class="__cf_email__" data-cfemail="137b62622a537077703d747c65">[email protected]</span></a>.
[[Page 19593]]
SUPPLEMENTARY INFORMATION: The sole source award will support the
government of Rwanda's vision of achieving and maintaining HIV epidemic
control and the UNAIDS goal of ending HIV/AIDS as a public health
threat by 2030.
RBC is in a unique position to conduct this work, as it possesses
not only the mandate but also has the capacities to manage donor funds
efficiently and in accordance with PEPFAR principles and United State
Government regulations. All health workers implementing PEPFAR-
supported HIV clinical services including HIV testing, Antiretroviral
Therapy, TB/HIV, prevention of mother to child transmission, and
laboratory services are Ministry of Health (MOH) staff. All health
facilities where PEPFAR-supported services are offered are under RBC
accreditation and authorization. RBC is successfully coordinating HIV
services in all health facilities countrywide. It is the only entity
capable of providing comprehensive services and integrating HIV into
the national health system to cover all Rwanda districts at each level.
Summary of the Award
Recipient: Rwanda Biomedical Center (RBC).
Purpose of the Award: The purpose of this award is to support a
sustainable, affordable, integrated, and country-led HIV/AIDS clinical
and public health program in Rwanda.
Amount of Award: For RBC, the approximate year 1 funding amount
will be $17,500,000 in Federal Fiscal Year (FYY) 2024 funds, subject to
the availability of funds. Funding amounts for years 2-5 will be set at
continuation.
Authority: This program is authorized under Public Law 108-25 (the
United States Leadership Against HIV AIDS, Tuberculosis and Malaria Act
of 2003) (22 U.S.C. 7601, et seq.) and Public Law 110-293 (the Tom
Lantos and Henry J. Hyde United States Global Leadership Against HIV/
AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008), and
Public Law 113-56 (PEPFAR Stewardship and Oversight Act of 2013).
Period of Performance: The period for this award will be September
30, 2024, through September 29, 2029.
Dated: March 13, 2024.
Jamie Legier,
Acting Director, Office of Grants Services, Centers for Disease Control
and Prevention.
[FR Doc. 2024-05776 Filed 3-18-24; 8:45 am]
BILLING CODE 4163-18-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on March 19, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.